Search

Adult foveomacular vitelliform dystrophy is a rare pathology. Less than 1% of the reported cases display perifoveal capillary permeability. The three-year follow-up period of the case revealed a rare form, which had not yet been documented. The patient was a 40-year-old female with normal visual acuity, and a minor complaint of metamorphopsia on the left eye. Retinography showed a perifoveal yellowish subretinal area OS.Angiography showed perifoveal leakage OS. Follow up showed that, over 3 years, capillary incompetence disappeared and the yellow area underwent alterations, becoming atrophic OS. Angiography also showed hyperfluorescence (windows defect). Towards the end, it resembled the appearance of late stage of Best's Disease. Distrofia viteliforme foveomacular do adulto é uma patologia rara. Menos de 1% dos casos relatados mostram permeabilidade capilar perifoveal. O acompanhamento de 3 anos deste paciente revelou uma forma rara, ainda pouco documentada. O paciente era uma mulher de 40 anos de idade com acuidade visual normal, mas com queixa de metamorfopsia leve no olho esquerdo. A retinografia mostrou uma área sub-retiniana amarelada, perifoveal, com hiperfluorescência na angiofluoresceinografia. O seguimento mostrou, em 3 anos, que a incompetência capilar desapareceu e que a área, antes amarelada, tornou-se atrófica, com hiperfluorescência na angiografia, lembrando o aspecto tardio da doença de Best.

The purpose of this study was to describe a prospective case series of 5 eyes treated with intravitreal ranibizumab injection for neovascular glaucoma (NVG). Five patients with clinically uncontrolled NVG secondary to proliferative diabetic retinopathy (4 patients) and central retinal vein occlusion (1 patient), non-responsive to maximal tolerable medication and panretinal photocoagulation, received intravitreal ranibizumab injection (0.5 mg). Patients were seen at 1st, 3rd and 7th day after the ranibizumab injection and when it was necessary. Success was defined as intraocular pressure (IOP) 21, despite maximal tolerable medication, underwent trabeculectomy with 0.5mg/ml mitomycin C (MMC) for 1 minute. Failure was defined as IOP > 21 mmHg, phthisis bulbi, loss of light perception or additional glaucoma surgery. The primary outcome was 6-month IOP control. Mean IOP before the ranibizumab injection was 37 mmHg (7 mmHg SD). Two out of five eyes underwent only ranibizumab injection, having an IOP control after the procedure. Three patients were submitted to trabeculectomy with MMC on the 7th day after the injection. At 6-month follow-up, the mean IOP was 12mmHg (3 mmHg SD). All eyes showed regression of rubeosis iridis and IOP control. Visual acuity improved in 2 eyes worsened in 1 eye, and remained stable in 2 eyes. These data suggest that intravitreal ranibizumab injection may be a useful tool in the treatment of NVG. O objetivo deste estudo foi descrever uma série de casos prospectivos de 5 olhos tratados com ranibizumabe intravítreo para glaucoma neovascular (GNV). Cinco pacientes com GNV refratário, secundário a retinopatia diabética proliferativa (4 pacientes) e oclusão de veia central da retina (1 paciente), não responsivos a terapia medicamentosa máxima tolerada e panfotocoagulação da retina, receberam ranibizumabe intravítreo (0,5 mg). Os pacientes foram vistos no 1º, 3º e 7º dia após a aplicação e conforme necessário. O sucesso foi definido como pressão intraocular (PIO) d"21 mmHg, com ou sem uso de medicação antiglaucomatosa. Aqueles com PIO > 21 mmHg, apesar da medicação máxima tolerada, foram submetidos à trabeculectomia com mitomicina C (MMC) 0,5mg/mL por 1 minuto. Falência foi definida como PIO > 21 mmHg, phthisis bulbi, perda da percepção de luz ou necessidade de cirurgia antiglaucomatosa adicional. O resultado primário avaliado foi o controle da PIO após 6 meses do procedimento. A PIO média antes da injeção era de 37 mmHg (DP=7 mmHg). Dois pacientes foram submetidos somente a injeção intravítrea de ranibizumabe, obtendo controle da PIO após o procedimento. Três pacientes foram submetidos à trabeculectomia com MMC no 7º dia após a injeção. Após 6 meses de seguimento, a PIO média era de 12 mmHg (DP=3 mmHg). Todos os olhos mostraram regressão da rubeosis iriana e controle da PIO. A acuidade visual melhorou em 2 olhos, piorou em 1 olho e permaneceu estável em 2 olhos. Estas informações sugerem que a injeção intravítrea de ranibizumabe pode ser uma ferramenta útil no tratamento do GNV.

OBJECTIVE: To analyze the recovery of visual acuity (VA) and graft survival after first episode of endothelial rejection in penetrating keratoplasty (PKP) treated with intravenous (IV) and topic corticosteroid. METHODS: Interventional, prospective, non-comparative case series study evolving 32 PKP patients in one year follow up, who presented first episode of corneal endothelial rejection. The patients were submitted to 500 mg IV injection of methylprednisolone in association with topical prednisolone. Main outcome measures included VA recovery and corneal edema regression. Second outcome included new rejections and graft failure. Multivariate analysis techniques were used to estimate rates of graft outcome events and the impact of risk factors. RESULTS: A total of 32 eyes from 32 patients (13 male and 19 female) were included in the study. The mean VA (in number of letters) before rejection was 48 (22 to 88 letters). Patients treated within 7 days or less of initial symptoms had better VA recovery, corneal edema regression and less graft failure (p

OBJETIVE: To describe the reattachment rate and visual acuity results of patients with uncomplicated rhegmatogenous retinal detachment who underwent segmental scleral buckle surgery. METHODS: Prospective case series of 100 patients with visual loss or symptoms (floaters and photopsia) of less than 30 days' duration scheduled for surgery. No patient had a retinal break greater than 30°, a retinal detachment larger than 2 quadrants or proliferative vitreoretinopathy. RESULTS: The 1-week, 1-month, and 6-month anatomical success rates were 93%, 100%, and 100%, respectively. Seven patients underwent one additional retinal detachment surgery (pars plan vitrectomy) after primary failure at 1-week follow-up. The preoperative, 1-month, and 6-month best correct visual acuity were 20/100, 20/80, and 20/50, respectively. The postoperative complications were: eyelid edema in 10% of the patients, transient ocular hypertension in 5%, macular pucker in 3%, transient diplopia in 3%, and hyphema (